BILIC, Sanela,HOWARD, JR., Danny Roland,CAMERON, John Scott
申请号：
HK18113602
公开号：
HK1254635A1
申请日:
2018.10.24
申请国别(地区):
HK
年份:
2019
代理人:
摘要：
The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease； a pharmaceutical composition comprising such combination； a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof； use of such combination for the treatment of proliferative disease； and a commercial package comprising such combination.
